Results 61 to 70 of about 98 (96)

Caracterización de las reacciones adversas medicamentosas en ancianos. Matanzas. 2005-2009 Characterization of the adverse drug reactions in elder people. Matanzas. 2005-2009

Revista Médica Electrónica, 2011
La presente investigación caracterizó las notificaciones de sospechas de reacciones adversas medicamentosas en personas mayores de 60 años, recibidas en la Unidad Coordinadora Provincial de Farmacovigilancia, desde el 1 de enero de 2005 al 31 de ...
Leidy Santos Muñoz, Legdy Mari Martínez Padrón   +1 more
doaj  

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Pharmacovigilance in Action: Utilizing VigiBase Data to Improve Clozapine Safety

Patient Preference and Adherence
Carlos De las Cuevas,1 Emilio J Sanz,2,3 Jose de Leon4,5 1Department of Internal Medicine, Dermatology, and Psychiatry and Instituto Universitario de Neurociencia (IUNE), Universidad de La Laguna, La Laguna, Canary Islands, Spain; 2Department of Physical
De las Cuevas C, Sanz EJ, de Leon J
doaj  

Falsificação de medicamentos no Brasil Falsificación de medicamentos en Brasil Counterfeiting of drugs in Brazil

Revista de Saúde Pública, 2012
OBJETIVO: Identificar os principais medicamentos falsificados apreendidos pela Polícia Federal brasileira e os estados em que houve a apreensão. MÉTODOS: Estudo retrospectivo descritivo dos laudos periciais elaborados por Peritos Criminais da Polícia ...
Joseane Ames, Daniele Zago Souza
doaj  

Introducing auto-disable syringes to the national immunization programme in Madagascar

Bulletin of the World Health Organization, 2003
OBJECTIVE: To evaluate the safety and coverage benefits of auto-disable (AD) syringes, weighed against the financial and logis- tical costs, and to create appropriate health policies in Madagascar.
Drain Paul K., Ralaivao Josoa S., Rakotonandrasana Alexander, Carnell Mary A.   +3 more
doaj  

Postmarketing surveillance Is not used to promote products: Avoid promotional studies [PDF]

BMJ, 1994
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Active Surveillance of Postmarket Medical Product Safety in the Federal Partners' Collaboration

Medical Care, 2012
After half a century of monitoring voluntary reports of medical product adverse events, the Food and Drug Administration (FDA) has launched a long-term project to build an adverse events monitoring system, the Sentinel System, which can access and evaluate electronic health care data to help monitor the safety of regulated medical products once they ...
Melissa A, Robb, Judith A, Racoosin, Chris, Worrall, Summer, Chapman, Trinka, Coster, Francesca E, Cunningham   +5 more
openaire   +2 more sources

Evaluation of the Relative Abuse of an OROS Extended-release Hydromorphone HCI Product

The Clinical Journal of Pain, 2018
Objective: Formulating prescription opioids to limit abuse remains a priority. OROS extended-release (ER) hydromorphone HCl (EXALGO) may have lower abuse potential than many other opioid products. Three postmarketing studies of the relative abuse liability of OROS hydromorphone ER were conducted.
Butler, Stephen F., McNaughton, Emily C., Black, Ryan A., Cassidy, Theresa A   +3 more
openaire   +3 more sources

Postmarket surveillance of natural health products in Canada: clinical and federal regulatory perspectivesThis article is one of a selection of papers published in this special issue (part 1 of 2) on the Safety and Efficacy of Natural Health Products.

Canadian Journal of Physiology and Pharmacology, 2007
Postmarket surveillance, particularly adverse reactions (ARs), forms an integral part of the ongoing safety evaluation for natural health products (NHPs). ARs can be related to many factors, including inherent toxicity, misuse, hypersensitivity, NHP–drug interactions, or product quality.
openaire   +1 more source

Postmarket surveillance of natural health products in Canada: clinical and federal regulatory perspectives.

Canadian journal of physiology and pharmacology, 2008
Postmarket surveillance, particularly adverse reactions (ARs), forms an integral part of the ongoing safety evaluation for natural health products (NHPs). ARs can be related to many factors, including inherent toxicity, misuse, hypersensitivity, NHP-drug interactions, or product quality. High consumer use and limited safety and efficacy data from human
openaire   +1 more source